Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Tralokinumab for AD was associated with sustained improvements in disease severity and no new safety signals at 12 months in a real-life study.

Congenital TORCH infections appear to be associated with an increased risk for intellectual disability and autism.

Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them are FDA-approved.

The use of vibration anesthesia in patients undergoing cryotherapy was associated with pain reductions when compared with cryotherapy alone.

BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents ...

Undeclared pharmacologically active ingredients are detected in one-third of over-the-counter skin products marketed online.

An active acupressure intervention offers clinical benefits for patients with rosacea when combined with pharmacotherapy.

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Quadrivalent HPV vaccination before pregnancy is associated with a lower risk for adverse pregnancy outcomes, including preterm birth.

The FDA has expanded the approval of Rhapsido (remibrutinib) to include symptomatic dermographism in adults inadequately controlled by H1 antihistamines, backed by phase 3 RemIND trial data.

The only baseline characteristic that predicted super response to topical ruxolitinib in patients with nonsegmental vitiligo was disease activity.